MD at Instituto Alexander Fleming, Argentina
Dr. Diego H. Enrico is an accomplished Medical Oncologist at the Alexander Fleming Cancer Institute in Buenos Aires, Argentina. He specializes in thoracic oncology and is the Coordinator of the Cancer Research and Innovation Unit. Dr. Enrico holds an MD from the University of Morón and completed his oncology residency at Eva Perón General Hospital. He further honed his expertise through a fellowship at the Gustave Roussy Cancer Center in Paris, focusing on translational and clinical cancer research. His research contributions include multiple clinical trials and numerous awards for his work in oncology, particularly in lung and prostate cancer. Dr. Enrico has co-authored several influential studies and received prestigious grants for cancer research. In addition to his clinical and research roles, he is an experienced educator and has served as co-director of research methodology programs. His ongoing work focuses on innovative cancer therapies and improving patient outcomes.
Education
Dr. Diego H. Enrico holds a robust academic background in both medicine and business. He earned a Bachelor’s degree in Business Administration from N° 7 Educational School in Luján, Buenos Aires, graduating Summa Cum Laude in 2002 with an impressive 9.9/10 GPA. Pursuing his passion for healthcare, Dr. Enrico then attended the University of Morón School of Medicine, where he completed his MD degree in 2013, graduating Cum Laude with a GPA of 8.89/10. He further specialized in Medical Oncology through a postgraduate degree from the University of Buenos Aires between 2013 and 2015. Dr. Enrico has enhanced his expertise in clinical oncology with advanced studies abroad, completing the European University Diploma in Translational and Clinical Cancer Research and the University Diploma of Clinical Oncology at Université Paris XI, France, in 2019. His international training underscores his dedication to improving cancer research and patient care.
Dr. Diego H. Enrico’s research interests are centered around clinical oncology, with a particular focus on thoracic oncology and innovative cancer treatments. His work delves into the development of targeted therapies for non-small cell lung cancer (NSCLC), emphasizing the genetic and molecular underpinnings of the disease, such as EGFR mutations and KRAS mutations. Dr. Enrico actively participates in clinical trials, contributing to the advancement of combination therapies and immunotherapy strategies, including the use of novel agents like amivantamab, nivolumab, and pembrolizumab. He is also dedicated to improving patient outcomes through translational research, bridging the gap between laboratory findings and clinical applications. Additionally, Dr. Enrico’s interests include investigating biomarkers for cancer prognosis and the evaluation of treatment responses, as well as optimizing the safety and efficacy of cancer therapies through remote monitoring systems and real-life studies in oncology. His contributions significantly impact the field of precision medicine and personalized cancer care.
Dr. Diego H. Enrico possesses a broad range of research skills, particularly in the field of clinical oncology, with a strong focus on thoracic oncology. His expertise includes designing and conducting clinical trials, with experience in Phase I, II, and III trials for advanced malignancies and targeted therapies. As the Coordinator of the Cancer Research and Innovation Unit at the Alexander Fleming Cancer Institute, he has honed his abilities in translational cancer research, contributing to numerous studies on innovative treatments for non-small cell lung cancer. His proficiency in biostatistics, clinical research methodology, and the use of patient-reported outcomes to improve therapy adherence further highlights his analytical and strategic thinking. Additionally, Dr. Enrico has received several prestigious awards for his scientific contributions and has successfully led collaborative projects funded by international grants. His deep understanding of oncological biomarkers and personalized medicine makes him a leading researcher in the oncology field.